IL225351A0 - Methods to inhibit the rapid proliferation of cells in cancers driven by egfr - Google Patents
Methods to inhibit the rapid proliferation of cells in cancers driven by egfrInfo
- Publication number
- IL225351A0 IL225351A0 IL225351A IL22535113A IL225351A0 IL 225351 A0 IL225351 A0 IL 225351A0 IL 225351 A IL225351 A IL 225351A IL 22535113 A IL22535113 A IL 22535113A IL 225351 A0 IL225351 A0 IL 225351A0
- Authority
- IL
- Israel
- Prior art keywords
- egfr
- methods
- cell proliferation
- inhibiting cell
- driven cancers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6568—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39329110P | 2010-10-14 | 2010-10-14 | |
| PCT/US2011/056457 WO2012051587A1 (en) | 2010-10-14 | 2011-10-14 | Methods for inhibiting cell proliferation in egfr-driven cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL225351A0 true IL225351A0 (en) | 2013-06-27 |
Family
ID=45938740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL225351A IL225351A0 (en) | 2010-10-14 | 2013-03-20 | Methods to inhibit the rapid proliferation of cells in cancers driven by egfr |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140024620A1 (enExample) |
| EP (1) | EP2627179A4 (enExample) |
| JP (1) | JP2013539795A (enExample) |
| KR (1) | KR20130139999A (enExample) |
| CN (2) | CN103153064B (enExample) |
| AU (1) | AU2011315831B2 (enExample) |
| BR (1) | BR112013008816A2 (enExample) |
| CA (1) | CA2810900A1 (enExample) |
| EA (1) | EA201390550A1 (enExample) |
| IL (1) | IL225351A0 (enExample) |
| MX (1) | MX2013004086A (enExample) |
| WO (1) | WO2012051587A1 (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| JP2011523646A (ja) | 2008-05-21 | 2011-08-18 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのリン誘導体 |
| AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| JP6469567B2 (ja) * | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| EP2844642B8 (en) * | 2012-05-05 | 2019-12-25 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| CN102977104A (zh) * | 2012-11-26 | 2013-03-20 | 盛世泰科生物医药技术(苏州)有限公司 | 2,4-二氯-7-氢-吡咯并（2,3）嘧啶的合成 |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| UA115388C2 (uk) * | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
| CN104761544B (zh) * | 2014-01-03 | 2019-03-15 | 北京轩义医药科技有限公司 | Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂 |
| CN106536503B (zh) * | 2014-04-18 | 2019-09-06 | 北京澳合药物研究院有限公司 | 一种酪氨酸激酶抑制剂及其用途 |
| JP6487527B2 (ja) * | 2014-07-04 | 2019-03-20 | チル ファーマシューティカル カンパニー リミテッド | スピロ環アリールリン酸化物及びアリールリン硫化物（ｓｐｉｒｏｃｙｃｌｉｃ ａｒｙｌ ｐｈｏｓｐｈｏｒｕｓ ｏｘｉｄｅ ａｎｄ ａｒｙｌ ｐｈｏｓｐｈｏｒｕｓ ｓｕｌｆｉｄｅ） |
| CN106699810A (zh) * | 2015-11-17 | 2017-05-24 | 清华大学 | 一种含氮杂环化合物及其制备方法与在抑制激酶活性中的应用 |
| WO2017088784A1 (zh) * | 2015-11-27 | 2017-06-01 | 正大天晴药业集团股份有限公司 | 氘修饰的Brigatinib衍生物、含有该化合物的药物组合物及其用途 |
| WO2017133663A1 (en) * | 2016-02-03 | 2017-08-10 | Shanghai Fochon Pharmaceutical Co., Ltd. | Phosphorus containing compounds as protein kinase inhibitors |
| CN107098887B (zh) * | 2016-02-22 | 2019-08-09 | 复旦大学 | 嘧啶类化合物 |
| WO2017200016A1 (ja) * | 2016-05-17 | 2017-11-23 | 公益財団法人がん研究会 | Ｅｇｆｒ－ｔｋｉ耐性を獲得した肺癌の治療薬 |
| SG11201901251SA (en) | 2016-08-29 | 2019-03-28 | Univ Michigan Regents | Aminopyrimidines as alk inhibitors |
| US11180482B2 (en) * | 2016-11-30 | 2021-11-23 | Ariad Pharmaceuticals, Inc. | Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors |
| JP2020510027A (ja) * | 2017-03-08 | 2020-04-02 | アリアド ファーマシューティカルズ，インコーポレーテッド | ５−クロロ−ｎ４−［２−（ジメチルホスホリル）フェニル］−ｎ２−｛２−メトキシ−４−［４−（４−メチルピペラジン−１−イル）ピペリジン−１−イル］フェニル｝ピリミジン−２，４−ジアミンを含む医薬製剤 |
| DK3656769T3 (da) * | 2017-07-19 | 2023-02-13 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Aryl-phosphor-oxygen-forbindelse som egfr-kinase-inhibitor |
| CN111527103A (zh) * | 2017-09-08 | 2020-08-11 | 科罗拉多大学董事会,法人团体 | 用于治疗或预防her驱动的抗药性癌症的化合物、组合物和方法 |
| EP3715343B1 (en) * | 2017-12-21 | 2024-02-14 | Shenzhen TargetRx, Inc. | Diphenylaminopyrimidine compound for inhibiting kinase activity |
| CN110305161A (zh) * | 2018-03-20 | 2019-10-08 | 暨南大学 | 2-氨基嘧啶类化合物及其应用 |
| CN110467637B (zh) * | 2018-05-09 | 2022-02-18 | 北京赛特明强医药科技有限公司 | 一种含有氧化膦类取代苯胺的双氨基氯代嘧啶类化合物、制备方法及其应用 |
| CN110467638A (zh) * | 2018-05-09 | 2019-11-19 | 北京赛特明强医药科技有限公司 | 一种含有间氯苯胺类取代基的双氨基氯代嘧啶类化合物、制备方法及其应用 |
| CN110526941A (zh) * | 2018-05-24 | 2019-12-03 | 北京赛特明强医药科技有限公司 | 一种含有间氯苯胺类取代基的吡咯并嘧啶类化合物、制备方法及其应用 |
| CN111836819A (zh) * | 2018-05-24 | 2020-10-27 | 北京赛特明强医药科技有限公司 | 一种含有芳胺基取代的吡咯并嘧啶类化合物、制备方法及其应用 |
| CN121471153A (zh) * | 2018-08-15 | 2026-02-06 | 江苏奥赛康药业有限公司 | 二氨基嘧啶类化合物及其应用 |
| US20220119431A1 (en) * | 2019-01-18 | 2022-04-21 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Salt of egfr inhibitor, crystal form, and preparation method therefor |
| CN111825719A (zh) * | 2019-04-15 | 2020-10-27 | 北京赛特明强医药科技有限公司 | 一种含有芳胺基取代的吡咯并嘧啶类化合物、制备方法及其应用 |
| WO2020216371A1 (zh) * | 2019-04-26 | 2020-10-29 | 江苏先声药业有限公司 | Egfr抑制剂及其应用 |
| CN112469713B (zh) * | 2019-06-21 | 2023-09-01 | 江苏豪森药业集团有限公司 | 芳基磷氧化物类衍生物抑制剂、其制备方法和应用 |
| AU2020300619A1 (en) | 2019-07-03 | 2022-01-27 | Sumitomo Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof |
| CN114430739A (zh) * | 2019-07-26 | 2022-05-03 | 贝达药业股份有限公司 | Egfr抑制剂、组合物及其制备方法 |
| WO2021018003A1 (zh) * | 2019-07-26 | 2021-02-04 | 贝达药业股份有限公司 | Egfr抑制剂、组合物及其制备方法 |
| CN112538072B (zh) * | 2019-09-21 | 2024-02-06 | 齐鲁制药有限公司 | 氨基嘧啶类egfr抑制剂 |
| CN114502564A (zh) * | 2019-09-26 | 2022-05-13 | 贝达药业股份有限公司 | Egfr抑制剂、组合物及其制备方法 |
| CN114430741A (zh) * | 2019-10-17 | 2022-05-03 | 贝达药业股份有限公司 | Egfr抑制剂、组合物及其制备方法 |
| US20230026840A1 (en) * | 2019-11-21 | 2023-01-26 | Tyk Medicines, Inc. | Compound used as egfr kinase inhibitor and use thereof |
| WO2021104441A1 (zh) * | 2019-11-29 | 2021-06-03 | 江苏先声药业有限公司 | 作为egfr激酶抑制剂的多芳基化合物 |
| JP2023513333A (ja) * | 2020-02-14 | 2023-03-30 | 貝達薬業股▲ふん▼有限公司 | キノリニル基ホスフィンオキシド化合物、並びにその組成物及び使用 |
| WO2021173677A1 (en) * | 2020-02-25 | 2021-09-02 | Dana-Farber Cancer Institute, Inc. | Potent and selective degraders of alk |
| WO2021190417A1 (zh) * | 2020-03-23 | 2021-09-30 | 齐鲁制药有限公司 | 新型氨基嘧啶类egfr抑制剂 |
| CN111777592B (zh) * | 2020-06-22 | 2021-06-18 | 温州医科大学 | 一种n4-(2,5-二甲氧基苯基)-嘧啶二胺类靶向ddr1抑制剂及其制备和应用 |
| TW202221000A (zh) | 2020-09-30 | 2022-06-01 | 英屬開曼群島商百濟神州有限公司 | 用於降解ｅｇｆｒ之雙功能化合物及相關使用方法 |
| CN116685583A (zh) * | 2020-10-30 | 2023-09-01 | 缆图药品公司 | 嘧啶化合物、组合物及其医药应用 |
| EP4237418B1 (en) * | 2020-10-30 | 2026-02-11 | Blueprint Medicines Corporation | Pyrimidine compounds, compositions, and medicinal applications thereof |
| EP4237088A1 (en) * | 2020-10-30 | 2023-09-06 | Blueprint Medicines Corporation | Pyrimidine compounds, compositions, and medicinal applications thereof |
| CN116710444A (zh) * | 2020-10-30 | 2023-09-05 | 缆图药品公司 | 嘧啶化合物、组合物及其医药应用 |
| WO2022127807A1 (zh) * | 2020-12-18 | 2022-06-23 | 江苏豪森药业集团有限公司 | 一种芳基磷氧化物类衍生物自由碱的晶型及其制备方法和应用 |
| US12643886B2 (en) | 2021-01-07 | 2026-06-02 | Ontario Institute for Cancer Research (OICR), The Governing Council of the University of Toronto, Sinai Health System | Isoindolinone aminopyrimidine compounds as inhibitors of NUAK kinases, compositions and uses thereof |
| AU2022205713A1 (en) * | 2021-01-07 | 2023-07-27 | Ontario Institute For Cancer Research (Oicr) | Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof |
| WO2022194269A1 (zh) * | 2021-03-19 | 2022-09-22 | 上海齐鲁制药研究中心有限公司 | 新型egfr降解剂 |
| WO2022199589A1 (zh) * | 2021-03-23 | 2022-09-29 | 南京明德新药研发有限公司 | 嘧啶衍生物 |
| CA3207015A1 (en) * | 2021-04-01 | 2022-10-06 | Tae Bo Sim | Pyrimidine derivative with inhibitory activity against protein kinases and therapeutic pharmaceutical composition including the same |
| WO2022227032A1 (en) * | 2021-04-30 | 2022-11-03 | Beigene (Beijing) Co., Ltd. | Egfr degraders and associated methods of use |
| EP4330251A4 (en) * | 2021-04-30 | 2025-03-05 | BeiGene Switzerland GmbH | EGFR DEGRADING AGENTS AND METHODS OF USE THEREOF |
| CN115677772B (zh) * | 2021-07-30 | 2023-08-18 | 浙江大学智能创新药物研究院 | 一种用于egfr激酶抑制剂的化合物、组合物及其应用 |
| WO2024005516A1 (ko) * | 2022-06-28 | 2024-01-04 | 보로노이 주식회사 | 헤테로아릴 유도체 화합물 및 이의 용도 |
| CN115260234A (zh) * | 2022-07-01 | 2022-11-01 | 江苏医药职业学院 | 一种2-氨基-4-氨基芳基磷氧基嘧啶化合物及其制备方法与应用 |
| CN116284001B (zh) * | 2023-01-30 | 2025-06-06 | 中国药科大学 | Dclk1抑制剂、制备方法、药物组合物和应用 |
| CN117187271B (zh) * | 2023-03-07 | 2024-08-27 | 艾博生物科技(上海)有限公司 | 编码激活性EGFR突变肽的免疫调节治疗mRNA组合物 |
| CN121319053A (zh) * | 2024-07-10 | 2026-01-13 | 中国科学院基础医学与肿瘤研究所(筹) | 一类带有二乙烯基磷酰基的2-氨基嘧啶类化合物及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03005696A (es) * | 2000-12-21 | 2003-10-06 | Glaxo Group Ltd | Pirimidinaminas como moduladores de angiogenesis. |
| CA2626479A1 (en) * | 2005-11-03 | 2007-05-18 | Irm Llc | Protein kinase inhibitors |
| JO2660B1 (en) * | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| US8314234B2 (en) * | 2006-09-25 | 2012-11-20 | Janssen Pharmaceutica N.V. | Bicyclic pyrimidine kinase inhibitors |
| TWI389893B (zh) * | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二（芳胺基）芳基化合物 |
| US7989465B2 (en) * | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| BRPI0908049A2 (pt) * | 2008-03-05 | 2015-08-11 | Novartis Ag | Uso de derivados de pririmidina para o tratamento de doenças dependentes de egfr ou de doenças que possuem resistência adquirida a agentes que são direcionados aos membros da família de egfr |
| AU2009233964B2 (en) * | 2008-04-07 | 2012-06-07 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| JP2011523646A (ja) * | 2008-05-21 | 2011-08-18 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのリン誘導体 |
| AU2009262068C1 (en) * | 2008-06-27 | 2015-07-02 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| ES2622138T3 (es) * | 2010-06-23 | 2017-07-05 | Hanmi Science Co., Ltd. | Nuevos derivados de pirimidina condensados para la inhibición de la actividad tirosina quinasa |
| JP5956999B2 (ja) * | 2010-11-01 | 2016-07-27 | セルジーン アヴィロミクス リサーチ， インコーポレイテッド | ヘテロアリール化合物およびその使用 |
| EP2637502B1 (en) * | 2010-11-10 | 2018-01-10 | Celgene CAR LLC | Mutant-selective egfr inhibitors and uses thereof |
-
2011
- 2011-10-14 KR KR1020137012320A patent/KR20130139999A/ko not_active Withdrawn
- 2011-10-14 WO PCT/US2011/056457 patent/WO2012051587A1/en not_active Ceased
- 2011-10-14 AU AU2011315831A patent/AU2011315831B2/en active Active
- 2011-10-14 CA CA2810900A patent/CA2810900A1/en not_active Abandoned
- 2011-10-14 BR BR112013008816A patent/BR112013008816A2/pt not_active IP Right Cessation
- 2011-10-14 JP JP2013534053A patent/JP2013539795A/ja active Pending
- 2011-10-14 CN CN201180049813.4A patent/CN103153064B/zh active Active
- 2011-10-14 EA EA201390550A patent/EA201390550A1/ru unknown
- 2011-10-14 US US13/878,744 patent/US20140024620A1/en not_active Abandoned
- 2011-10-14 CN CN201510102987.2A patent/CN104814970A/zh active Pending
- 2011-10-14 EP EP11833524.9A patent/EP2627179A4/en not_active Withdrawn
- 2011-10-14 MX MX2013004086A patent/MX2013004086A/es not_active Application Discontinuation
-
2013
- 2013-03-20 IL IL225351A patent/IL225351A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013004086A (es) | 2013-07-05 |
| CN103153064B (zh) | 2015-04-22 |
| KR20130139999A (ko) | 2013-12-23 |
| EP2627179A1 (en) | 2013-08-21 |
| US20140024620A1 (en) | 2014-01-23 |
| AU2011315831A1 (en) | 2013-03-28 |
| AU2011315831B2 (en) | 2015-01-22 |
| JP2013539795A (ja) | 2013-10-28 |
| EP2627179A4 (en) | 2014-04-02 |
| CN104814970A (zh) | 2015-08-05 |
| WO2012051587A1 (en) | 2012-04-19 |
| CN103153064A (zh) | 2013-06-12 |
| CA2810900A1 (en) | 2012-04-19 |
| BR112013008816A2 (pt) | 2016-06-28 |
| EA201390550A1 (ru) | 2013-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2627179A4 (en) | METHODS OF INHIBITING CELL PROLIFERATION IN EGFR-INDUCED CANCERS | |
| IL228739B (en) | Compounds to inhibit cell proliferation in egfr-driven cancers | |
| SI2558577T1 (sl) | Bifunkcionalni kompleksi in metode za pripravo in uporabo takšnih kompleksov | |
| SG10201403962SA (en) | Luggage processing station | |
| IL223147A0 (en) | Means and methods for dignosing pancreatic cancer in a subject | |
| GB201016139D0 (en) | Cancer phosholipidome | |
| GB201017421D0 (en) | Cell | |
| IL255309A0 (en) | Reprogramming of cancer cells | |
| GB2485395B (en) | Coin apparatus | |
| SI2534242T1 (sl) | Izboljšan sestavek za inhibicijo tumorske celične proliferacije | |
| TWI561405B (en) | Improvements in security substrates for security documents | |
| PL2601319T3 (pl) | Rozprowadzająca rynna zsypowa | |
| GB201013765D0 (en) | Selfweighing luggage device | |
| GB2478843B (en) | Improvements in dielectrics | |
| GB201204932D0 (en) | Improvements in arrangements for deploying | |
| GB201104924D0 (en) | Improvements in headphones | |
| EP2844642B8 (en) | Compounds for inhibiting cell proliferation in egfr-driven cancers | |
| IL223436A (en) | Methods for preparing tetranor - pgdm and tetranor - pgjm | |
| GB201016989D0 (en) | Cell induction | |
| GB201019108D0 (en) | Cell | |
| PH32010000084S1 (en) | Patch pocket | |
| GB201003074D0 (en) | Directionality in reading | |
| GB201104637D0 (en) | Improvements in arrangements for deploying | |
| GB201020580D0 (en) | Cells | |
| GB201019304D0 (en) | Cells |